My PCR
Create Account
Logo PCR

20 May 2026

Stents, scaffolds and DCB

Navigating the complexity of high bleeding risk

Session comprising selected EuroPCR 2026 abstract submissions

Moderators: G. Richardt, M. Valgimigli
Speakers: B. Cortese, N. Mankerious, U. Kaul, J. Yun, V. A. Jimenez Diaz, B. B. Ke

Summary

Focusing on patients with high bleeding risk undergoing PCI, this session presents contemporary evidence on prevalence, procedural strategies with different stent types, antiplatelet therapy considerations including diabetic and sex-specific outcomes, and novel technologies such as sirolimus-coated balloons and machine learning models for restenosis prediction.

Presentations available when logged in:

  • Prevalence, temporal trends and characteristics of high bleeding risk patients in TRANSFORM II randomised controlled trial
  • Complex PCI with biodegradable polymer or durable polymer DES in patients at high bleeding risk.
  • Presence of high bleeding risk and the choice of antiplatelet agents in diabetics - Lessons learnt from TUXEDO 2
  • Sex-specific long-term outcomes in high bleeding risk patients undergoing PCI
  • Bioderadable or durable polymer DES in patients at high bleeding risk with target-vessel tortuosity
  • Sirolimus-coated balloon with single antiplatelet therapy in high bleeding risk PCI
Related Content
Sirolimus-Eluting Balloon vs. Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary... A novel bailout technique for the percutaneous extraction of an entrapped coronary guidewire beneath a crushed stent The next frontier of DCB is to simplify complexity
Recommended for you
1-year SELUTION DeNovo results: DEB strategy vs. systematic DES in de novo coronary disease IRONMAN II: 2-year outcomes of sirolimus-eluting bioresorbable scaffolds vs. DES PCRonline @ TCT 2025 - The international perspective